The Ocular Tissue Engineering Laboratory conducts translational research by combining world-leading clinical care with cutting-edge cellular and molecular technologies to provide a comprehensive platform for understanding and treating retinal diseases. Our group pioneered multimodal retinal imaging in patients with retinal diseases.
The Ocular Tissue Engineering Laboratory houses one of Australia’s largest patient tissue and DNA biobanks, providing an invaluable resource for retinal disease modelling research. Our biobank enables patient skin cells to be converted into retinal tissues in the laboratory, allowing the study of disease in affected tissue derived from the patient.
Using these patient-derived retinal tissues, we are developing gene therapies and new pharmacological treatments for retinal diseases such as retinitis pigmentosa, Stargardt disease, Usher syndrome and other genetic conditions of the retina. Our mission is to find cures for this most common cause of blindness in working-age Australians.